-
Study aim
-
To determine the effectiveness of topical application of 0.5% Timolol Maleate in chronic recalcitrant heel fissures
-
Design
-
A Single-arm non randomized clinical trial with a group design of 150 patents enrolled between 06 June 2023 and 12 December 2023, and followed up for 1 month.
-
Settings and conduct
-
The study will be conducted on patients reporting in dermatology out-patient-department of a Tertiary care hospital. Data will be collected on a pre-designed proforma. Patients' anonymity will be maintained by keeping their identity hidden, and a code will be generated for them. Confidentiality of the data will be maintained by restricting the data only to the first author or the direct author/s who will collect the data.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: patients with chronic heel, plantar fissures.
Ages between 18 to 75 years
Both genders included
Exclusion criteria: Patients taking oral beta blockers
Known allergy to beta blockers
Patients with chronic dermatosis affecting feet i.e. psoriasis, Reiter's syndrome, keratoderma etc.
-
Intervention groups
-
Intervention group includes 150 patients having heel fissures, with no control group for comparison. All will be advised to apply 2-3 drops of Timolol Maleate 0.5% on heel fissures at bet time for 2 weeks, A follow-up will be requested after 2 weeks and 4 weeks of application.
-
Main outcome variables
-
Quantitative Variables : age, humidity, room temperature, Measurement of Heel Fissures
Qualitative variables, such as Gender, Diabetes, Acute or Chronic Diseases, Pre-existing Skin Condition, Hydra/Aqua Working Environment, Exposure to the chemical on routine basis, Regular use of closed foot ware, Prolong standing workstation and scaling variables such as Severity Scale of Skin, and Photographic Scaling of Heel